Amicus Therapeutics to Present at LEERINK Roundtable Series: Rare Disease & Immuno-Oncology

CRANBURY, N.J., Sept. 22, 2016 -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology in New York, NY on September 28, 2016 at 3:05pm ET.

An audio webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.

FOLD–G

CONTACTS:

Investors/Media:
Amicus Therapeutics
Sara Pellegrino
Senior Director, Investor Relations
[email protected] 
(609) 662-5044

Media:
MWW PR
Sean Conley
[email protected] 
(646) 381-9096